N
NEUROPHET
Leading provider of neuro-navigation technology, that enables clinicians to treat patients more precisely
About NEUROPHET
Neurophet is a medical software company specializing in advanced neuroscience technologies to overcome medical limitations. The company focuses on developing software for the computational analysis of transcranial electrical stimulation (tES), including transcranial Direct Current Stimulation (tDCS) and transcranial Alternating Current Stimulation (tACS). Their flagship product, Neurophet tES LAB, offers easy and powerful FEM (Finite Element Method) simulation of stimulation effects using personalized brain models. This software significantly reduces research time, making it possible to conduct complex brain engineering studies in minutes. Neurophet serves researchers and medical professionals in the brain stimulation field, providing them with cutting-edge tools to accelerate their studies. The company operates in the medical software market and generates revenue through software licensing. Neurophet has been recognized for its user-friendly interface design, winning the Red Dot Award in 2018, and has been selected into the Philips Healthworks global startup program.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2016
- Headquarters
- Seoul, South Korea
- Listing
- IPO 2025
- Employees
- 77
- Open positions
- None listed
- Dealroom signal
- 74.1/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Core AI, Spinout, AI Applications, DT and LS, science-based
- Technology
- Artificial Intelligence, Deep Tech, Machine Learning
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Apr 2026 | $0 | — | Undisclosed | ↗ |
| POST IPO CONVERTIBLE✓Other financing | Apr 2026 | $0 | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth |
|---|---|---|
| 2026 | $2.2M | 0% |
| 2025 | $2.2M | +18% |
| 2024 | $1.9M | +41.9% |
| 2023 | $1.3M | +141.4% |
| 2022 | $543K | — |
Growth signals
Latest recorded traffic for NEUROPHET is 7.7K monthly website visits, up 2.7% over the last three months. NEUROPHET's team declined 1.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
FuturePlay
Series A4 investors entered at this stage
SBI Investment Korea
The Wells Investment- PMPrafit Asset Management
- JIJCurve Investment
Series B and later11 investors entered at this stage
Industrial Bank of Korea
Solidus Investment
QUAD Ventures
DB Financial Investment
Mirae Asset Securities (HK)
KB Investment
Kolon Investment- XIXolon Invest
Profit Investments
Seoil & M- ALAlly
Other known investors2 additional known investors
Gwangju Institute of Science and Technology
Daedeok Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NEUROPHET on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NEUROPHET’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.